Figure 8 schematically depicts a hypothesis for the ability of Tg6F and ezetimibe to ameliorate that portion of dyslipidemia and systemic inflammation that is due to WD-mediated increases in IFN-β, CH25H, and 25-OHC. This evidence concerns the gene IFNB1 and metabolic syndrome.